Skip to main content

Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody.

Publication ,  Journal Article
Ryan, MT; Spicer, KM; Frei-Lahr, D; Samei, E; Frey, GD; Hargrove, H; Bloodworth, G
Published in: Health Phys
November 2000

The Medical University of South Carolina is currently participating in clinical trials of 131I radiolabeled Anti-B1 antibody for treatment of Non-Hodgkin's lymphoma. Under current South Carolina Department of Health and Environmental Control regulatory guidelines,; these patients are required to be admitted to the hospital and to remain as inpatients until the whole body burden is <30 mCi or the exposure rate measured 1 m from the patient is <5 mR h(-1). We demonstrate that these patients can be released in accordance with the new recommended guidelines of the Nuclear Regulatory Commission for the release of patients containing radioactive materials in compliance with all radioactive material and public dose standards. This benefits these patients by reducing their risk of infection and other hospital insults and by reducing the length of hospitalizations. Further, unnecessary hospital admissions are decreased, and the overall cost of healthcare delivery for these patients is significantly reduced.

Duke Scholars

Published In

Health Phys

DOI

ISSN

0017-9078

Publication Date

November 2000

Volume

79

Issue

5 Suppl

Start / End Page

S52 / S55

Location

United States

Related Subject Headings

  • Radiotherapy Dosage
  • Radioimmunotherapy
  • Outpatients
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Lymphoma, Non-Hodgkin
  • Iodine Radioisotopes
  • Humans
  • Health Physics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ryan, M. T., Spicer, K. M., Frei-Lahr, D., Samei, E., Frey, G. D., Hargrove, H., & Bloodworth, G. (2000). Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody. Health Phys, 79(5 Suppl), S52–S55. https://doi.org/10.1097/00004032-200011001-00004
Ryan, M. T., K. M. Spicer, D. Frei-Lahr, E. Samei, G. D. Frey, H. Hargrove, and G. Bloodworth. “Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody.Health Phys 79, no. 5 Suppl (November 2000): S52–55. https://doi.org/10.1097/00004032-200011001-00004.
Ryan MT, Spicer KM, Frei-Lahr D, Samei E, Frey GD, Hargrove H, et al. Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody. Health Phys. 2000 Nov;79(5 Suppl):S52–5.
Ryan, M. T., et al. “Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody.Health Phys, vol. 79, no. 5 Suppl, Nov. 2000, pp. S52–55. Pubmed, doi:10.1097/00004032-200011001-00004.
Ryan MT, Spicer KM, Frei-Lahr D, Samei E, Frey GD, Hargrove H, Bloodworth G. Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody. Health Phys. 2000 Nov;79(5 Suppl):S52–S55.

Published In

Health Phys

DOI

ISSN

0017-9078

Publication Date

November 2000

Volume

79

Issue

5 Suppl

Start / End Page

S52 / S55

Location

United States

Related Subject Headings

  • Radiotherapy Dosage
  • Radioimmunotherapy
  • Outpatients
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Lymphoma, Non-Hodgkin
  • Iodine Radioisotopes
  • Humans
  • Health Physics